
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) November 16, 2010

PRESSURE BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in its Charter)

MASSACHUSETTS

(State or Other Jurisdiction of Incorporation)

0-21615

(Commission File Number)

04-2652826

(IRS Employer Identification No.)

14 Norfolk Avenue, South Easton, MA

(Address of Principal Executive Offices)

02375

(Zip Code)

(508) 230-1828

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 2.02 Results of Operations and Financial Condition

On November 16, 2010, the Company issued a press release announcing its financial results for the quarter ended September 30, 2010. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

Limitation on Incorporation by Reference. The information furnished in this Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

| <u>Exhibit Number</u> | <u>Exhibit Description</u> |
|-----------------------|--|
| 99.1 | Press release dated November 16, 2010 of Pressure BioSciences, Inc. announcing its financial results for the quarter ended September 30, 2010. |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 17, 2010

PRESSURE BIOSCIENCES, INC.

By: /s/ Richard T. Schumacher

Richard T. Schumacher
President and Chief Executive Officer

EXHIBIT INDEX

| Exhibit Number | Exhibit Description |
|-----------------------|--|
| 99.1 | Press release dated November 16, 2010 of Pressure BioSciences, Inc. announcing its financial results for the quarter ended September 30, 2010. |

FOR IMMEDIATE RELEASE

Investor Contacts:

Richard T. Schumacher, President & CEO
R. Wayne Fritzsche, Chairman
Joseph L. Damasio, Jr., Controller

Pressure BioSciences, Inc.
(508) 230-1828 (T)

**Pressure BioSciences, Inc. Announces Continued Strong Financial
Performance for the Third Quarter and Year-to-Date 2010**

South Easton, MA, November 16, 2010 — Pressure BioSciences, Inc. (NASDAQ: PBIO) (“PBI” or the “Company”) today announced continued strong financial performance for the three and nine month periods ended September 30, 2010, compared to the same periods in 2009. The Company also provided a brief business update.

Total revenue for the third quarter of 2010 was \$372,103 compared to \$317,427 for the comparable period in 2009, a 17% increase. Revenue from the sale of pressure cycling technology (PCT) products and services was \$194,730 for the three months ended September 30, 2010 compared to \$204,584 for the same period in 2009. During the third quarter of 2010, the Company completed the installation of fifteen (15) Barocycler instruments, compared to twenty (20) during the same period of 2009. Fourteen of the fifteen instruments were domestic installations and one was an international sale, compared to nineteen domestic installations and one international sale for the same quarter in 2009. Sales of PCT-based consumables generated revenue of approximately \$22,000 for the three months ended September 30, 2010 compared to approximately \$18,000 for the same period in 2009, an increase of approximately 22%.

Operating loss for Q3 2010 was \$842,587 compared to \$754,180 for the same period in 2009. After the exclusion of non-cash charges, operating cash burn for the third quarter of 2010 was approximately \$711,000, compared to approximately \$597,000 for the third quarter of 2009, an increase of about 19%.

Total revenue for the nine months ended September 30, 2010 was \$1,065,020 compared to \$894,570 for the same period in 2009, a 19% increase. Revenue from the sale of PCT products and services was \$667,262 for the nine months ended September 30, 2010 compared to \$585,928 for the same period in 2009, a 14% increase. During the first nine months of 2010, the Company installed thirty-seven Barocycler instruments, as compared to forty-two during the same period of 2009. Thirty-six of the thirty-seven instruments were domestic installations and one was an international sale, compared to thirty-five domestic installations and seven international sales for the same nine-month period in 2009. Sales of PCT-based consumables generated revenue of \$81,096 for the nine months ended September 30, 2010 compared to \$58,816 for the same period in 2009, a 38% increase.

Operating loss for the nine months ended September 30, 2010 was \$2,551,685 compared to \$2,419,424 for the same period in 2009. After the exclusion of non-cash charges, operating cash burn for the nine months ended September 30, 2010 was approximately \$2,156,000, compared to approximately \$1,914,000 for the same period in 2009, a 13% increase.

Loss per common share – basic and diluted – was \$0.26 for the third quarter of 2010 compared to \$0.35 for the third quarter of 2009. Loss per common share – basic and diluted – was \$1.01 for the nine months ended September 30, 2010 compared to \$1.07 for the same nine-month period of 2009. The loss per common share for the nine months ended September 30, 2010 and 2009 included an income tax benefit of \$244,479 and \$623,262 respectively.

Joseph L. Damasio, Jr., Corporate Controller, commented: "Operating cash usage for the three and nine month periods ended September 30, 2010 was approximately 19% and 13% higher than for the same periods in 2009, respectively. These added costs reflect investments made in inventory, marketing, sales, and PCT applications development to support our goal of increasing both PCT System and consumables sales. Importantly, some of these application development costs are being returned to us through a \$244,000 "Therapeutic Discovery Grant" award from the U.S. government, as recently reported."

R. Wayne Fritzsche, Chairman of the Board of Directors, said: "In addition to our continued strong financial performance, the Company reported other important achievements during the third quarter of 2010, including:

- Initial equity research coverage by two independent investment research firms: Zacks Investment Research and TriPoint Global Research.
- A collaboration with the Lawrence Berkeley National Laboratory (LBNL) to study microbes in oil spills. In August 2010, LBNL scientists reported on the discovery of a new type of oil-eating bacteria and the potential for natural microbial clean-up of oil spills. LBNL scientists use the PCT System as their sample preparation method of choice.
- A front page story on the benefits of PCT in Genetic Engineering and Biotechnology News (GEN), the most widely read biotechnology publication in the world.
- A special supplement of Expert Review of Proteomics focused entirely on the May 21st symposium at Harvard Medical School on *Applications of Ultra-high Pressure in Biotechnology*. The symposium, co-hosted by several Harvard groups, included presentations on the advantages of PCT by 14 scientists from prestigious laboratories in North America.
- The addition of two distinguished members to our Board of Directors, Mr. Alan Goldberg and Mr. Greg Freitag."

Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. said: "We continue to leverage the majority of internal efforts on driving the installed base of PCT Systems and increasing consumables usage. Our focus remains in the area of sample preparation for mass spectrometry and forensics, where we have had the most success in closing accounts over the past year, where we believe the advantages of PCT are clear, and where we believe the benefits of PCT exceed those of competitive methods."

Mr. Schumacher concluded: "Discussions with possible strategic partners on co-marketing and co-development deals are on-going; we are optimistic that an agreement will be finalized soon. We are also continuing to look at all available options related to financing the Company, not just for the short-term, but for the long-term as well. We are confident that we will successfully close on one of these options in the near future."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a NASDAQ Capital Markets listed publicly traded company focused on the development and sale of instrumentation and consumables based on a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 14 US and 10 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification. PBI currently focuses its efforts on the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, histology, and counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include statements that additional expenditures for marketing, sales, and PCT applications development in 2010 versus 2009 will help increase both PCT System and consumables usage; that some of these expenditures will be returned to PBI through the "Therapeutic Discovery Grant" Award; that LBNL scientists use the PCT System as their sample preparation method of choice; that PBI has had the most success in closing accounts in the area of mass spectrometry and forensics sample preparation; that the use of the PCT System for the mass spectrometry and forensics sample preparation areas have clear advantages and benefits over other sample preparation methods; that the Company will finalize a co-marketing/co-development agreement soon; and that the Company will close on a financing transaction in the near future. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: the Company's financial results for the quarter and nine months ended September 30, 2010 may not necessarily be indicative of future results as future revenues may not meet expectations due to the possible failure of the Company's products to achieve commercial acceptance, changes in customer's needs and technological innovations, and expenses that may be higher than anticipated due to unforeseen costs or cost increases; the risk that the Company may be unable to improve total revenue, PCT consumables revenue, and the number of PCT Systems installations because potential customers may not believe that the PCT System will provide any significant advantages over other sample preparation systems; that due to unexpected costs or increases in costs, the Company will need additional capital sooner than anticipated; possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of PCT; changes in customer's needs and technological innovations; and the Company's sales force may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods. Further, the Company expects that it will need additional capital to fund its continuing operations beyond the first quarter of 2011. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website <http://www.pressurebiosciences.com>

**Consolidated Statements of Operations
(Unaudited)**

| | For the Three Months Ended September 30, | | For the Nine Months Ended September 30, | |
|---|---|---------------------|--|-----------------------|
| | 2010 | 2009 | 2010 | 2009 |
| REVENUE: | | | | |
| PCT products, services, other | \$ 194,730 | \$ 204,584 | \$ 667,262 | \$ 585,928 |
| Grant revenue | 177,373 | 112,843 | 397,758 | 308,642 |
| Total revenue | <u>372,103</u> | <u>317,427</u> | <u>1,065,020</u> | <u>894,570</u> |
| COSTS AND EXPENSES: | | | | |
| Cost of PCT products and services | 86,285 | 74,093 | 300,360 | 305,156 |
| Research and development | 382,054 | 273,286 | 980,338 | 895,556 |
| Selling and marketing | 313,412 | 254,022 | 890,265 | 784,902 |
| General and administrative | 432,939 | 470,206 | 1,445,742 | 1,328,380 |
| Total operating costs and expenses | <u>1,214,690</u> | <u>1,071,607</u> | <u>3,616,705</u> | <u>3,313,994</u> |
| Operating loss | (842,587) | (754,180) | (2,551,685) | (2,419,424) |
| Interest income | <u>438</u> | <u>731</u> | <u>1,560</u> | <u>4,418</u> |
| Loss before income taxes | (842,149) | (753,449) | (2,550,125) | (2,415,006) |
| Income tax benefit | 244,479 | - | 244,479 | 623,262 |
| Net loss | <u>(597,670)</u> | <u>(753,449)</u> | <u>(2,305,646)</u> | <u>(1,791,744)</u> |
| Accrued and deemed dividends on convertible preferred stock | (95,205) | (22,504) | (408,767) | (546,187) |
| Net loss applicable to common shareholders | <u>\$ (692,875)</u> | <u>\$ (775,953)</u> | <u>\$ (2,714,413)</u> | <u>\$ (2,337,931)</u> |
| Net loss per share attributable to common stockholders - basic and diluted | \$ (0.26) | \$ (0.35) | \$ (1.01) | \$ (1.07) |
| Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation | 2,687,853 | 2,195,283 | 2,683,706 | 2,195,283 |

**Consolidated Balance Sheets
(Unaudited)**

| | <u>September 30, 2010</u> | <u>December 31, 2009</u> |
|--|-------------------------------|------------------------------|
| ASSETS | | |
| CURRENT ASSETS | | |
| Cash and cash equivalents | \$ 948,550 | \$ 1,609,778 |
| Restricted cash | 20,011 | 20,012 |
| Short-term investments | 248,000 | - |
| Accounts receivable, net of allowances of \$26,820 at September 30, 2010 and \$8,400 at December 31, 2009 | 194,370 | 203,211 |
| Income tax receivable | 244,479 | - |
| Inventories | 1,132,820 | 638,350 |
| Deposits | 6,472 | 182,010 |
| Prepaid income taxes | 1,442 | 3,176 |
| Prepaid expenses and other current assets | 55,884 | 86,563 |
| Total current assets | <u>2,852,028</u> | <u>2,743,100</u> |
| PROPERTY AND EQUIPMENT, NET | <u>223,623</u> | <u>249,465</u> |
| OTHER ASSETS | | |
| Intangible assets, net | 194,552 | 231,026 |
| TOTAL ASSETS | <u>\$ 3,270,203</u> | <u>\$ 3,223,591</u> |
| LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| CURRENT LIABILITIES | | |
| Accounts payable | \$ 323,216 | \$ 148,087 |
| Accrued employee compensation | 195,879 | 105,824 |
| Accrued professional fees and other | 221,625 | 271,926 |
| Deferred revenue | 17,519 | 8,058 |
| Total current liabilities | <u>758,239</u> | <u>533,895</u> |
| LONG TERM LIABILITIES | | |
| Deferred revenue | 10,300 | 1,609 |
| TOTAL LIABILITIES | <u>768,539</u> | <u>535,504</u> |
| COMMITMENTS AND CONTINGENCIES | | |
| STOCKHOLDERS' EQUITY | | |
| Series A convertible preferred stock, \$.01 par value; 313,960 designated shares; 262,135 shares issued and outstanding on September 30, 2010 and 152,213 shares on December 31, 2009 (Liquidation value of \$3,014,553) | 2,621 | 1,523 |
| Series B convertible preferred stock, \$.01 par value; 279,256 designated shares; 88,711 shares issued and outstanding on September 30, 2010 and 62,039 shares on December 31, 2009 (Liquidation value of \$1,667,767) | 887 | 620 |
| Common stock, \$.01 par value; 20,000,000 shares authorized; 2,687,853 shares issued and outstanding on September 30, 2010 and 2,328,426 shares issued and outstanding on December 31, 2009 | 26,879 | 23,284 |
| Warrants to acquire preferred stock and common stock | 1,132,675 | 1,352,165 |
| Additional paid-in capital | 12,022,301 | 9,297,115 |
| Accumulated deficit | <u>(10,683,699)</u> | <u>(7,986,620)</u> |
| Total stockholders' equity | 2,501,664 | 2,688,087 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | <u>\$ 3,270,203</u> | <u>\$ 3,223,591</u> |